Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy
Riley J. Arseneau, Emma Kempster, Carley Bekkers, Thomas Samson, Boris Gala-López, Ravi Ramjeesingh, J. Boudreau, Thomas Arnason
Abstract
• Phase 2 trials are underway for zolbetuximab therapy in pancreatic adenocarcinoma. • Claudin 18 (43–14A clone) immunohistochemistry determines zolbetuximab eligibility. • Claudin 18 expression with 43–14A is unclear in pancreatic adenocarcinoma. • We found 32.5 % of PDACs express Claudin 18 using the 43–14A antibody clone. • Claudin 18 expression associates with lower grade and better median overall survival. Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, with a five-year survival rate below 15 %. Claudin 18.2 (CLDN18.2) has emerged as a novel potential therapeutic target in PDAC. Zolbetuximab, a monoclonal antibody targeting CLDN18.2, has demonstrated therapeutic benefit in gastric cancers and is now in phase 2 clinical trials for PDAC. Trial eligibility for zolbetuximab requires tumor membranous immunohistochemical staining with the pan-claudin 18 companion diagnostic antibody clone 43–14A. However, the expression of CLDN18 detected using this clone has only been evaluated in 62 patients from a single retrospective study. Herein, we report immunohistochemical staining using 43–14A on surgically resected PDAC samples ( n = 120). Samples were stained following the protocol used in clinical trials, using the 43–14A VENTANA antibody in a prediluted kit, and according to the manufacturer's recommended protocol. Positive cases were defined as ≥ 75 % of tumor cells exhibiting membranous staining with an intensity of ≥ 2+. Out of 120 PDAC cases, 39 (32.5 %) stained positive for CLDN18 with 43–14A. A significant association was observed between lower tumor grade and higher 43–14A staining ( p < 0.05). CLDN18-positive cases demonstrated significantly improved survival at the cohort's median overall survival (23 months, p < 0.05), suggesting that claudin expression could serve as a both a diagnostic and prognostic marker. Our findings indicate that 32.5 % of PDAC tumors in this cohort are positive for CLDN18, suggesting that a significant proportion of patients with PDAC could benefit from zolbetuximab and other CLDN18.2 targeted immunotherapies if pancreatic cancer therapeutic trials prove successful.